Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
AzurRx BioPharma, Inc is a biotechnology business based in the US. AzurRx BioPharma shares (AZRX) are listed on the NASDAQ and all prices are listed in US Dollars. AzurRx BioPharma employs 12 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$0.85|
|52-week range||$0.54 - $2.50|
|50-day moving average||$0.77|
|200-day moving average||$1.07|
|Wall St. target price||$3.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.90|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-25)||N/A|
|1 month (2021-07-02)||6.25%|
|3 months (2021-05-05)||2.16%|
|6 months (2021-02-01)||N/A|
|1 year (2020-08-01)||N/A|
|2 years (2019-08-01)||N/A|
|3 years (2018-08-01)||N/A|
|5 years (2016-08-01)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-151.52%|
|Return on equity TTM||-402.41%|
|Market capitalisation||$46.9 million|
TTM: trailing 12 months
There are currently 2.5 million AzurRx BioPharma shares held short by investors – that's known as AzurRx BioPharma's "short interest". This figure is 41.3% up from 1.7 million last month.
There are a few different ways that this level of interest in shorting AzurRx BioPharma shares can be evaluated.
AzurRx BioPharma's "short interest ratio" (SIR) is the quantity of AzurRx BioPharma shares currently shorted divided by the average quantity of AzurRx BioPharma shares traded daily (recently around 952897.68339768). AzurRx BioPharma's SIR currently stands at 2.59. In other words for every 100,000 AzurRx BioPharma shares traded daily on the market, roughly 2590 shares are currently held short.
However AzurRx BioPharma's short interest can also be evaluated against the total number of AzurRx BioPharma shares, or, against the total number of tradable AzurRx BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AzurRx BioPharma's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 AzurRx BioPharma shares in existence, roughly 30 shares are currently held short) or 0.032% of the tradable shares (for every 100,000 tradable AzurRx BioPharma shares, roughly 32 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AzurRx BioPharma.
Find out more about how you can short AzurRx BioPharma stock.
We're not expecting AzurRx BioPharma to pay a dividend over the next 12 months.
Over the last 12 months, AzurRx BioPharma's shares have ranged in value from as little as $0.54 up to $2.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AzurRx BioPharma's is 1.5191. This would suggest that AzurRx BioPharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
AzurRx BioPharma, Inc. , a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc.
Everything we know about the Chobani IPO, plus information on how to buy in.
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.